Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €38.36 EUR
Change Today -0.14 / -0.36%
Volume 65.5K
GNFT On Other Exchanges
Symbol
Exchange
Berlin
OTC US
As of 7:53 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

genfit (GNFT) Snapshot

Open
€39.00
Previous Close
€38.50
Day High
€39.00
Day Low
€38.20
52 Week High
02/20/15 - €70.64
52 Week Low
05/26/14 - €20.25
Market Cap
919.0M
Average Volume 10 Days
295.1K
EPS TTM
€-0.76
Shares Outstanding
24.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENFIT (GNFT)

Related News

No related news articles were found.

genfit (GNFT) Related Businessweek News

No Related Businessweek News Found

genfit (GNFT) Details

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases, primarily in the field of hepato-gastroenterology worldwide. It offers diagnostic solutions in various therapeutic areas, such as metabolic diseases, liver diseases, non-alcoholic steato-hepatitis (NASH), cholestatic liver diseases, inflammation and autoimmune diseases, and inflammatory bowel diseases. The company’s lead pipeline product comprises GFT505, which is in Phase II clinical trials for the treatment of NASH. It is also developing TGFTX1 program that targets the ROR?t receptor, which directs IL-17 mediated immunity to treat inflammatory and auto-immune diseases; and TGFTX3 program that develops proprietary compounds, which activate the nuclear receptor Rev-Erba for metabolic and inflammatory diseases, including NASH and type 2 diabetes. The company also develops TGFTX4 program that inhibits the proliferation and the pro-fibrotic activation of primary human hepatic stellate cells; TGFTX5 program for chronic inflammatory bowel diseases; and SAN/GFT-2 program to develop molecules, which correct the mitochondrial dysfunction associated with certain pathologies comprising type 2 diabetes and kidney diseases. Genfit SA was founded in 1999 and is headquartered in Loos, France.

81 Employees
Last Reported Date: 04/3/15
Founded in 1999

genfit (GNFT) Top Compensated Officers

Founder, Chairman of The Executive Board and ...
Total Annual Compensation: €408.2K
Chief Financial & Administrative Officer and ...
Total Annual Compensation: €106.5K
Executive Vice President and Member of Manage...
Total Annual Compensation: €81.2K
Compensation as of Fiscal Year 2013.

genfit (GNFT) Key Developments

Genfit SA Reports Consolidated Earnings Results for the Year Ended Dec. 31, 2014

Genfit SA reported consolidated earnings results for the year ended Dec. 31, 2014. For the year, the company reported total income of EUR 6.77 million compared to EUR 5.97 million a year ago. Current operating loss was EUR 16.22 million compared to EUR 10.42 million a year ago. Net loss was EUR 17.02 million compared to EUR 12.65 million a year ago.

Genfit SA Presents at CF&B European Small Cap Event, Apr-27-2015

Genfit SA Presents at CF&B European Small Cap Event, Apr-27-2015 . Venue: Paris, France.

Genfit SA Presents at 40th Annual Deutsche Bank Health Care Conference, May-07-2015 08:40 AM

Genfit SA Presents at 40th Annual Deutsche Bank Health Care Conference, May-07-2015 08:40 AM. Venue: The InterContinental Hotel, 510 Atlantic Ave, Boston, MA 02210, United States. Speakers: Dean W. Hum, Chief Operating Officer, Chief Scientific Officer and Member of The Executive Board, Jean-François Mouney, Founder, Chairman of the Executive Board and Chief Executive Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNFT:FP €38.36 EUR -0.14

GNFT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GNFT.
View Industry Companies
 

Industry Analysis

GNFT

Industry Average

Valuation GNFT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 123.8x
Price/Book 12.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 114.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENFIT, please visit www.genfit.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.